New Haven CT 克罗恩病临床试验
8项针对 克罗恩病的研究正在 New Haven及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
招募中1 期
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
招募中3 期
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
招募中2 期
- Yale University School of Medicine /ID# 266786, New Haven
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
招募中3 期
- Medical Research Center of Connecticut, Hamden · 距离 6 英里
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
招募中3 期
- Yale University Digestive Disease-Site Number: 8400108, New Haven
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
招募中4 期
- Medical Research Center of Connecticut, LLC, Hamden · 距离 6 英里
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
招募中
- Yale University, New Haven
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
招募中观察性研究
- Yale University School of Medicine, New Haven
其他城市的 克罗恩病试验
- New York City, NY35 项研究
- Boston, MA19 项研究
- Miami, FL19 项研究
- Cleveland, OH19 项研究
- St. Louis, MO19 项研究
- Tyler, TX17 项研究
- Houston, TX17 项研究
- Orlando, FL17 项研究
- Atlanta, GA17 项研究
- San Antonio, TX15 项研究
- San Diego, CA15 项研究
- Los Angeles, CA15 项研究
New Haven的其他研究
- 非小细胞肺癌41 项研究
- 乳腺癌38 项研究
- 癌症（所有类型）33 项研究
- 转移性癌症23 项研究
- 肺癌22 项研究
- 头颈鳞状细胞癌22 项研究
- 卵巢癌21 项研究
- 结直肠癌20 项研究
- 前列腺癌20 项研究
- 急性髓系白血病17 项研究
- 酒精使用障碍 (AUD)17 项研究
- 阿片类药物过量17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。